Advertisement
Singapore markets closed
  • Straits Times Index

    3,290.70
    +24.75 (+0.76%)
     
  • Nikkei

    38,229.11
    +155.13 (+0.41%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • Bitcoin USD

    60,866.07
    -1,981.66 (-3.15%)
     
  • CMC Crypto 200

    1,261.69
    -96.32 (-7.09%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • Dow

    39,512.84
    +125.08 (+0.32%)
     
  • Nasdaq

    16,340.87
    -5.40 (-0.03%)
     
  • Gold

    2,366.90
    +26.60 (+1.14%)
     
  • Crude Oil

    78.20
    -1.06 (-1.34%)
     
  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     
  • FTSE Bursa Malaysia

    1,600.67
    -0.55 (-0.03%)
     
  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     
  • PSE Index

    6,511.93
    -30.53 (-0.47%)
     

Teva offers EU concessions over Allergan generics deal - EU

Teva Pharmaceutical Industries' Jerusalem oral solid dosage plant (OSD) is seen December 21, 2011. Israel-based Teva is the world's leading generic drugmaker. REUTERS/Ronen Zvulun

BRUSSELS (Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.TA) has offered concessions to allay antitrust concerns over its $40.5 billion bid for Allergan's (AGN.N) generics unit, European Union regulators said on Friday.

"Commitments have been submitted and the new legal deadline is set on 10 March," European Commission spokesman Ricardo Cardoso said in an email, without providing details.

Acquiring the Actavis generic business would strengthen Teva's position as the world's largest generics drugmaker.

(Reporting by Foo Yun Chee. editing by Julia Fioretti)